FDA Issues Draft Guidance on Rare Diseases
The agency revised draft guidance to enable more efficient and successful drug development programs for the treatment or prevention of rare diseases.
On Jan. 17, 2019, FDA announced that it issued a revised draft guidanceto enable more efficient and successful drug development programs for the treatment or prevention of rare diseases.
The draft guidance, Rare Diseases: Common Issues in Drug Development Guidance for Industry, was originally issued in 2015. The revised guidance covers a range of topics such as natural history studies, use of biomarkers, and methods for demonstrating effectiveness and safety.
Comments and suggestions should be submitted within 60 days of publication.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
